A Service For Professionals Monday, October 23, 2017
Contact (202) 540-8337
Biotechnology News Today
A Service For Professionals Monday, October 23, 2017 11614 Sources 411,422,507 Articles 3,134,516 Readers
Contact (202) 540-8337

Immunomic Therapeutics Gets Chimeric Vaccines Notice of US Patent Allowance

/EINPresswire.com/ Lancaster, PA, & Rockville, MD August 2nd, 2012 - Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, announced that the U.S. Patent and Trademark Office is providing a Notice of Allowance for ITI's "Chimeric Vaccines" patent in the US. This protection specifically covers vectors utilizing the company's proprietary Lysosomal Associated Membrane Protein (LAMP) LAMP DNA vaccine platform, the core design and technology utilized in ITI's improved LAMP-based DNA vaccine vectors being applied in the company's R&D pipeline and clinical studies. This allowance rounds out ITI's worldwide chimeric patent portfolio including allowances in Europe, Japan and Australia.

ITI's VP of R&D, Dr. Teri Heiland, explained, "The invention covered under this patent represents a unique innovation in DNA vaccines. Specifically, our improved LAMP vector allows us to generate an enhanced immunological response in comparison to other DNA vaccine technologies. This Notice of Allowance represents a great day for the LAMP vaccine platform technology and ensures protection of our LAMP technology until 2022."

CEO, Bill Hearl, Ph.D., offered, "this US patent allowance is part of an integrated strategy to commercialize a growing pipeline of leading DNA vaccine platform Intellectual Property currently fueling ITI's emerging LAMP DNA vaccine businesses."

The Chimeric Vaccines invention provides for chimeras of proteins and nucleic acids to generate vaccines against selected antigens. The chimeras encode antigenic sequences and domains for trafficking to an endosomal compartment, directing the antigenic protein to the MHC-II compartment in the cell, promoting enhanced immune response.

LAMP technology has demonstrated highly promising results at the research level and is being aggressively commercialized by ITI under exclusive worldwide license from Johns Hopkins University and its original inventor, Distinguished JHU Professor Dr. J. Thomas August, M.D.

Immunomic Therapeutics is currently implementing LAMP in the clinic with an investigational allergy vaccine for the treatment of rhinocinjunctivitis to Japanese Red Cedar. ITI has begun an open label, Phase I, clinical study designed to establish the safety of the LAMP-vax platform. The primary objective of this Phase I Study is to evaluate both the safety and immunological response of therapeutic doses and the dosing regimen of JRC-LAMP-Vax™ vaccine as it applies to allergy patients. The study, being conducted in allergy clinical centers based in Atlanta, GA, is expected to be complete in the Fall of 2012.

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on its patented LAMP Technology platform. LAMP-vax™ vaccine technology significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.

x x x

Dr. Bill Hearl, President / CEO
Phone: 1-717-327-1919
Immunomix @ gmail.com Immunomic Therapeutics, Inc.
313 W. Liberty St., #343, Lancaster, PA 17603
E-mail: info@immunomix.com
Web: http://www.immunomix.com
Powered by EIN Presswire